Jardiance (Empagliflozin) Employer & ICHRA Coverage: How to Get It Cheaper in 2026

What Does Jardiance Actually Cost, and Why Does It Vary So Much?

Jardiance has a published list price near $650 per 30-day supply as of 2026, but the number you pay depends almost entirely on which coverage layer you land in. Women on commercial employer plans, ICHRA arrangements, or marketplace policies face three very different pricing realities.

Understanding that gap is the first step to closing it.

The Three Price Tiers Most Women Encounter

Tier 1: Commercial employer insurance with a formulary position. If your employer's pharmacy benefit manager (PBM) has placed Jardiance on Tier 2 or Tier 3, your copay typically runs $30 to $90 per fill. Empagliflozin's cardiovascular and renal trial data have pushed most large PBMs to keep it on formulary for type 2 diabetes and heart failure indications, because denying it creates downstream cost liability.

Tier 2: High-deductible health plans (HDHPs) before the deductible clears. You pay the plan's negotiated rate, often $180 to $320 per fill, until your deductible resets. Pairing an HDHP with an HSA (see below) is the single most effective tool here.

Tier 3: No insurance or government programs. Medicare Part D beneficiaries gained a $2,000 annual out-of-pocket cap under the Inflation Reduction Act starting in 2025, and Jardiance's monthly cost under Part D has dropped meaningfully for women with diabetes or heart failure. Medicaid coverage varies by state formulary.

How Employer Insurance Covers Jardiance in 2026

Most mid-size and large employer plans cover Jardiance for its FDA-approved indications. Coverage for off-label uses, including PCOS-related insulin resistance or perimenopausal metabolic management, is inconsistent and often requires a prior authorization (PA) letter from your prescriber.

Getting a Prior Authorization Approved

PA requirements most often apply when Jardiance is prescribed for:

• Type 2 diabetes without documented metformin failure
• Heart failure with preserved ejection fraction (HFpEF) at the 10 mg dose, even though the EMPEROR-Preserved trial demonstrated significant reduction in the composite of cardiovascular death or hospitalization
• Chronic kidney disease without diabetes, despite the EMPA-KIDNEY trial supporting this indication

Your prescriber's office handles the PA paperwork, but you can speed it up by confirming your plan's specific step-therapy requirement beforehand. Call the member services number on your insurance card and ask: "What step-therapy drugs are required before Jardiance for [your diagnosis code]?"

What to Do If Your Employer Plan Denies Coverage

A denial is not final. Under the No Surprises Act and standard plan grievance rules, you have the right to an internal appeal and then an external independent review. Your prescriber should submit a Letter of Medical Necessity (LMN) citing the 2023 AHA/ACC heart failure guideline or the KDIGO 2024 CKD guideline if either applies to your case.

ICHRA and Jardiance: What Women Need to Know

An Individual Coverage Health Reimbursement Arrangement (ICHRA) is an employer-funded account that reimburses you for individual health insurance premiums and, depending on plan design, eligible out-of-pocket medical expenses.

How ICHRA Reimbursement Works for Prescription Costs

ICHRA reimbursement rules follow IRS Section 213(d) definitions of eligible medical expenses. Jardiance qualifies. Your employer sets the monthly allowance (there is no IRS cap for employers), and you submit receipts for reimbursement.

Practical steps:

1. Confirm your ICHRA is a "premium-only" plan or a "premium-plus" plan. Only the latter reimburses drug copays directly.
2. Buy an individual marketplace plan that places Jardiance on its formulary before you enroll. The HealthCare.gov drug formulary lookup lets you check before you commit.
3. Save every pharmacy receipt and explanation of benefits (EOB). Most ICHRA administrators accept PDF uploads through a mobile app.
4. Stack your ICHRA allowance with the Lilly savings card (see next section). ICHRA reimbursement applies to your remaining balance after the manufacturer card credits your account, as long as your plan design permits third-party payments.

The stacking order that minimizes your cost in 2026: Lilly savings card credits first at the pharmacy counter, then ICHRA reimbursement covers whatever copay or coinsurance remains, then HSA dollars cover any gap if your plan is HSA-compatible. Women who apply all three layers report effective monthly costs of $0 to $15 in WomanRx patient intake surveys.

The Lilly Savings Card: Exact Terms for 2026

Lilly's Jardiance savings program offers eligible patients a co-pay as low as $10 per 30-day supply. The card applies to commercially insured patients only. Medicare, Medicaid, TRICARE, and other federal or state government plans are excluded by federal anti-kickback rules.

Eligibility Checklist

• You have commercial insurance (employer, ICHRA-purchased marketplace plan, or individual market)
• Your insurance covers Jardiance (even if you owe a copay or coinsurance)
• You are a US resident
• You are not enrolled in any government health program as your primary coverage

How to Activate and Use It

1. Enroll at Lilly's patient savings portal or ask your pharmacist to apply it at the point of sale.
2. The card saves up to $150 per fill (maximum $1,800 per year in most iterations of the program, though Lilly adjusts terms periodically; verify at enrollment).
3. Present the card every fill. It does not auto-renew at the pharmacy without the card number.
4. If your pharmacy does not accept it, use GoodRx or a 90-day mail-order fill through your PBM to reduce per-unit cost while you resolve the card issue.

Programs change frequently. Confirm current terms directly with Lilly at 1-800-545-5979 or at the savings card portal before relying on any specific dollar figure.

HSA and FSA: Using Pre-Tax Dollars for Jardiance

Jardiance is an eligible medical expense under IRS Publication 502, which means you can pay for it with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds.

HSA: The Better Long-Term Tool

An HSA is available only if you are enrolled in a qualifying HDHP. In 2026, the IRS contribution limit is $4,300 for self-only coverage and $8,550 for family coverage. Contributions are triple-tax-advantaged: deductible going in, tax-free growth, and tax-free withdrawal for medical expenses.

For a woman paying $200 per fill in her HDHP deductible phase, using HSA dollars saves approximately $56 per fill in federal income tax alone at a 28% marginal rate. Over 12 months before the deductible clears, that is roughly $336 in avoided taxes.

FSA: Use-It-or-Lose-It, but Immediate Access

An FSA funds your full annual election on day one of the plan year, which can bridge the gap while you wait for HSA funds to accumulate. The 2026 FSA contribution limit is $3,300. You cannot hold both an HSA and a standard healthcare FSA simultaneously, though a limited-purpose FSA (dental and vision only) is permitted alongside an HSA.

Other Ways to Reduce Your Jardiance Cost

Patient Assistance Programs (PAPs)

If you are uninsured and your household income is at or below 400% of the federal poverty level, the Lilly Insulin Value Program and Lilly's broader patient assistance program may provide Jardiance at no cost. Apply through Lilly's enrollment portal or ask your WomanRx provider to submit on your behalf.

90-Day Supply at Mail Order

Most employer plans discount the per-fill cost for 90-day mail-order fills versus 30-day retail. A fill that costs $80 at retail may cost $60 through mail order for the same 90-day supply, effectively 25% less per day of therapy. Ask your PBM (CVS Caremark, Express Scripts, OptumRx) whether Jardiance is available at the mail-order discount tier.

GoodRx and Pharmacy Discount Cards

GoodRx prices for Jardiance fluctuate by pharmacy but have run between $540 and $620 for a 30-day supply, which is not meaningfully better than the list price. GoodRx coupons cannot be combined with insurance or the Lilly savings card. Use GoodRx only if you are uninsured and ineligible for the Lilly PAP.

Jardiance and Women's Health: Sex-Specific Physiology You Need to Know

Most of the trial data on empagliflozin comes from mixed-sex populations, and women were underrepresented in the landmark EMPA-REG OUTCOME trial, which enrolled approximately 29% women. The cardiovascular mortality benefit, a 38% relative risk reduction in cardiovascular death versus placebo, was seen across sexes in that trial, but the absolute benefit in women specifically has wider confidence intervals. This is an honest evidence gap.

SGLT2 Inhibitors and the Female Urogenital Tract

SGLT2 inhibitors increase glucose excretion in the urine, and that mechanism creates a specific risk for women: genital mycotic infections. In clinical trials, genital mycotic infections occurred in approximately 10% of women on empagliflozin versus 1.5% on placebo. Urinary tract infections were modestly increased as well.

Practical management:

• Maintain good genital hygiene, particularly after swimming or exercise.
• Report any itching, discharge, or odor promptly. Recurrent infections may require a short break from therapy and antifungal treatment.
• Women who are prone to bacterial vaginosis may see more frequent episodes. Discuss prophylactic strategies with your provider.

Empagliflozin Across Life Stages

Reproductive years with PCOS. Empagliflozin is not FDA-approved for PCOS, but emerging data suggest that SGLT2 inhibition reduces insulin resistance and androgen levels in women with PCOS, potentially improving menstrual regularity. This is extrapolated evidence, not a direct trial in PCOS populations of meaningful size. If your prescriber recommends it off-label for PCOS, insurance coverage is much less likely without a diabetes diagnosis.

Perimenopause and menopause. Estrogen decline accelerates visceral fat accumulation and worsens insulin resistance. Women with type 2 diabetes lose approximately 2 to 3 kg of body weight on empagliflozin over 24 weeks, a modest but real benefit in the perimenopausal period when weight management becomes harder. The drug also reduces blood pressure by 3 to 5 mmHg systolic, which may complement menopause-related cardiovascular risk increases.

Postmenopause and bone. SGLT2 inhibitors have been associated with increased fracture risk in some analyses, particularly with canagliflozin in the CANVAS trial. Empagliflozin did not show a significant increase in fracture risk in EMPA-REG OUTCOME, but postmenopausal women already at elevated fracture risk should have a bone density discussion with their provider before starting any SGLT2 inhibitor.

Pregnancy, Lactation, and Contraception: Required Reading

Empagliflozin is contraindicated in the second and third trimesters of pregnancy. Animal studies show fetal renal toxicity when SGLT2 inhibitors are given during the period of renal development, which begins in the second trimester. The FDA label for Jardiance states that use during the second and third trimesters can cause fetal renal toxicity, oligohydramnios, and related complications including limb contractures, delayed skull ossification, neonatal death, and pulmonary hypoplasia.

Human data in the first trimester are limited. The current recommendation from most maternal-fetal medicine specialists is to discontinue empagliflozin as soon as pregnancy is confirmed, and ideally before conception if planning a pregnancy.

Contraception requirement. Women of reproductive age taking empagliflozin for type 2 diabetes, heart failure, or CKD should use reliable contraception and have a clear plan for switching to pregnancy-compatible diabetes management (typically insulin with or without metformin) if pregnancy is desired. Discuss this transition plan with your WomanRx provider before you start Jardiance.

Lactation. Animal data show empagliflozin is present in rat milk. No adequate human lactation studies exist. Given the potential for renal effects in nursing infants and the absence of safety data, the FDA label advises against breastfeeding during empagliflozin treatment. If you are postpartum and breastfeeding, discuss insulin or metformin as alternatives until weaning.

Postpartum. Women with gestational diabetes have a 40 to 60% lifetime risk of developing type 2 diabetes, and empagliflozin may eventually be part of their long-term management after breastfeeding ends. Early lifestyle intervention and metformin remain first-line postpartum, but empagliflozin is a reasonable consideration once you have stopped breastfeeding and your cardiovascular risk profile warrants it.

Who This Is Right For, and Who Should Look at Other Options

Women Most Likely to Benefit from Pursuing Jardiance Coverage

• Women with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, particularly in perimenopause and postmenopause when cardiometabolic risk rises sharply
• Women with heart failure (HFrEF or HFpEF) regardless of diabetes status, given the EMPEROR-Preserved evidence showing a 21% relative risk reduction in CV death or HF hospitalization
• Women with type 2 diabetes and chronic kidney disease (eGFR 20 to 45 mL/min/1.73m²), where the EMPA-KIDNEY data showed a 28% reduction in CKD progression or cardiovascular death
• Women on commercial employer plans or ICHRA-purchased marketplace plans who can access the Lilly savings card

Women Who Should Use a Different Approach or Drug

• Women who are pregnant, planning pregnancy in the near term, or breastfeeding (see pregnancy section above)
• Women with type 1 diabetes: empagliflozin is not FDA-approved for type 1, and off-label use carries elevated diabetic ketoacidosis risk, which is already higher in women
• Women with recurrent genital mycotic infections or recurrent UTIs who cannot manage the increased frequency on SGLT2 inhibitors
• Women on Medicaid or Medicare as primary coverage: the Lilly savings card does not apply, and you should instead ask your provider about patient assistance program eligibility or whether dapagliflozin (Farxiga) has better formulary positioning on your specific plan

Step-by-Step Action Plan: Getting Jardiance Cheaper Starting This Week

1. Call your plan's member services line and ask for Jardiance's formulary tier, your cost-sharing amount, and whether a PA is required for your diagnosis.
2. Ask your prescriber's office to submit a PA if needed, citing your specific FDA-approved indication and the relevant trial or guideline.
3. Enroll in the Lilly savings card at the pharmacy counter or online before your next fill.
4. Check your ICHRA plan documents (or ask your HR department) whether drug copays are reimbursable expenses under your arrangement.
5. Elect or adjust your HSA contribution to cover anticipated out-of-pocket drug costs before your deductible resets.
6. Request 90-day mail-order fills through your PBM once coverage is confirmed, to lower per-unit cost.
7. Set a calendar reminder to verify the Lilly savings card terms at each plan-year renewal. Programs change at least annually.